PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
30610805-0	2018	The expression of PD-L1 in patients with castrate prostate cancer treated with enzalutamide.	enzalutamide	79-91	CD274 molecule	Homo sapiens	18-23	
34011528-0	2021	Flightless I homolog reverses enzalutamide resistance through PD-L1-mediated immune evasion in prostate cancer.	enzalutamide	30-42	CD274 molecule	Homo sapiens	62-67	
34011528-5	2021	Mechanism studies demonstrated that FLII physically interacted with YBX1 to inhibit nuclear localization of YBX1 and thereby suppress transcription of PDL1 in enzalutamide-resistant tumors.	enzalutamide	159-171	CD274 molecule	Homo sapiens	151-155	
34011528-6	2021	Restoration of FLII expression reversed enzalutamide resistance through activation of T-cell responses in the tumor microenvironment through inhibition of the YBX1/PD-L1 pathway.	enzalutamide	40-52	CD274 molecule	Homo sapiens	164-169	
32616555-2	2020	A published report showed that men with prostate cancer who were resistant to the second-generation androgen receptor inhibitor enzalutamide had increased programmed death-ligand 1 (PD-L1) expression on circulating antigen-presenting cells.	enzalutamide	128-140	CD274 molecule	Homo sapiens	155-180	
32616555-2	2020	A published report showed that men with prostate cancer who were resistant to the second-generation androgen receptor inhibitor enzalutamide had increased programmed death-ligand 1 (PD-L1) expression on circulating antigen-presenting cells.	enzalutamide	128-140	CD274 molecule	Homo sapiens	182-187	
30610805-1	2018	PURPOSE: The purpose of our retrospectively study was to evaluate the PD-L1 expression in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide.	enzalutamide	173-185	CD274 molecule	Homo sapiens	70-75	
25428917-0	2015	PD-L1 is highly expressed in Enzalutamide resistant prostate cancer.	enzalutamide	29-41	CD274 molecule	Homo sapiens	0-5	
28893901-3	2017	Furthermore, the androgen antagonist enzalutamide has been shown to upregulate PD-L1 expression in prostate cancer preclinical models.	enzalutamide	37-49	CD274 molecule	Homo sapiens	79-84	
35013615-1	2022	Early clinical data indicate that some patients with castration-resistant prostate cancer may benefit from program death ligand-1 (PD-L1) inhibition, especially with enzalutamide.	enzalutamide	166-178	CD274 molecule	Homo sapiens	131-136	
34945784-7	2021	Treatment (abiraterone, enzalutamide, radiotherapy, checkpoint-inhibitors) influenced PD-L1+ CTC levels.	enzalutamide	24-36	CD274 molecule	Homo sapiens	86-91